Lung cancer is one of the malignant tumors with the fastest growing incidence and mortality rates and the greatest threat to the health and lives of the population. According to the statistics, the global incidence and mortality rate of lung cancer are the first among all malignant tumors in men, and the second in women. In recent years, due to the large number of smokers and serious air pollution, the incidence and mortality rate of lung cancer in China has been rising steeply, and it is expected that by 2025, the number of lung cancer patients in China will reach 1 million, becoming the world’s largest lung cancer country. The incidence of lung cancer is insidious, and the early diagnosis rate of lung cancer in China is extremely low, and more than 80% of patients have lost the opportunity of surgery when they are diagnosed. Therefore, for most of the patients, the best choice is to combine multi-modality treatment, and transvascular interventional treatment for lung cancer is an extremely important part of the combined treatment. Transvascular intervention for lung cancer, including percutaneous arterial infusion chemotherapy and percutaneous arterial embolization, is a minimally invasive procedure and has become the first-line standard treatment option for lung cancer. The general method is to insert a catheter after percutaneous arterial puncture under local anesthesia, find the tumor blood supply vessel (usually bronchial artery) and then perfuse chemotherapy drugs through the catheter, followed by embolization of the tumor vessel with embolic agent to block the tumor blood supply. In this way, local lung cancer tumor tissues receive high concentration of chemotherapeutic drugs to increase the anti-tumor effect and reduce the side effects of systemic drugs, while embolization of tumor blood supply vessels deprives local tumor of blood nutrition and further controls tumor growth. Indications for transvascular intervention: (1) middle and advanced stage lung cancer who have lost surgical treatment; (2) lung cancer who cannot tolerate surgery; (3) lung cancer with difficulty in surgery, preoperative intervention is performed to reduce the difficulty of surgery and improve the efficacy of surgical treatment after short-term tumor reduction (equivalent to neoadjuvant chemotherapy before surgery); (4) lung cancer with hemoptysis. (5) Patients who cannot tolerate systemic intravenous chemotherapy, especially elderly and frail lung cancer patients; (6) For patients who can tolerate the dose of systemic intravenous chemotherapy, intravascular interventional chemotherapy + supplemental dose of intravenous chemotherapy is feasible to increase the local therapeutic effect and ensure the systemic dose; Case: Patient Li, male, 63 years old, with He was admitted to our department with “coughing sputum with blood for 3 months, accompanied by shortness of breath for one month”. Preoperative enhanced CT: the tumor was located in the pulmonary hilum, invading the pulmonary artery and compressing the bronchus. The tumor had no chance of surgical resection. Director Zhou Yubin of the Department of Interventional Oncology formulated a comprehensive treatment plan of transvascular intervention combined with systemic intravenous chemotherapy. The patient’s intraoperative imaging was successful, and postoperative chemotherapy was combined with systemic intravenous chemotherapy. The patient’s symptoms of shortness of breath were significantly relieved that night, with good results. Transvascular interventional treatment for lung cancer has the advantages of minimally invasive, low side effects and significant efficacy, and is more effective when combined with multiple means of synergistic treatment.